Chelation therapy with IV EDTA did not improve cardiovascular outcomes for adults with diabetes and prior heart attack, despite reducing blood lead levels.

TACT2 trial found that chelation therapy, involving IV infusions of EDTA to reduce lead levels, did not improve cardiovascular outcomes for adults with diabetes and prior heart attack. Although it reduced blood lead levels, there was no significant impact on mortality or cardiovascular events. The trial suggests chelation therapy should not be used for risk reduction in stable post-MI patients with diabetes.